地诺孕素在子宫内膜异位症相关性疼痛中的治疗作用:从基础到临床

doi:10.6040/j.issn.1671-7554.0.2024.0936

摘要/Abstract

摘要： 疼痛是子宫内膜异位症(endometriosis, EMs)患者的最主要症状,其发病机制复杂。地诺孕素作为EMs相关性疼痛治疗的关键药物之一,在EMs的长期管理中具有举足轻重的地位。本文通过深入剖析EMs相关性疼痛的发病机制,并从多项研究证据证实地诺孕素可以通过多种作用机制缩小EMs病灶、减轻炎症反应、调节神经生长因子、调控中枢神经过敏等,从而达到控制EMs疾病进展以及缓解疼痛的治疗效果,为进一步深入研究地诺孕素的作用机制以及临床应用效果提供科学依据。

关键词: 子宫内膜异位症, 神经性疼痛, 发病机制, 炎症微环境, 地诺孕素

Abstract: Pain is the main symptom of patients with endometriosis(EMs). The pathogenesis of endometriosis-associated pain is complex. Dienogest, as one of the key drugs for the treatment of EMs associated pain, plays a crucial role in the long-term management of EMs. This review deeply analyzed the pathogenesis of EMs associated pain, and confirmed that in multiple research evidence, dienogest can reduce EMs lesions, alleviate inflammatory reactions, regulate nerve growth factors, and control central nervous system allergies through various mechanisms of action, thereby achieving the therapeutic effect of controlling the progression of EMs and relieving pain. It provides scientific basis for further in-depth research on the mechanism and clinical application effects of dienogest.

Key words: Endometriosis, Neuropathic pain, Pathogenesis, Inflammatory microenvironment, Dienogest

中图分类号:

R711.71

梁炎春,严莹,麦华希,姚书忠. 地诺孕素在子宫内膜异位症相关性疼痛中的治疗作用:从基础到临床[J]. 山东大学学报 (医学版), 2025, 63(10): 27-33.

LIANG Yanchun, YAN Ying, MAI Huaxi, YAO Shuzhong. Therapeutic effect of dienogest in endometriosis-associated pain: from fundamental research to clinical practice[J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 27-33.

参考文献

[1] 中国医师协会妇产科医师分会, 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症诊治指南(第三版)[J]. 中华妇产科杂志, 2021, 56(12): 812-824. Chinese Obstetricians and Gynecologists Association, Cooperative Group of Endometriosis, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guideline for the diagnosis and treatment of endometriosis(Third edition)[J]. Chinese Journal of Obstetrics and Gynecology, 2021, 56(12): 812-824.
[2] Wei YJ, Liang YC, Lin HS, et al. Autonomic nervous system and inflammation interaction in endometriosis-associated pain[J]. J Neuroinflammation, 2020, 17(1): 80. doi:10.1186/s12974-020-01752-1
[3] Yang RY, Yang F, Wei YJ, et al. Hypoxia-induced semaphorin 3A promotes the development of endometriosis through regulating macrophage polarization[J]. Int Immunopharmacol, 2024, 138: 112559. doi:10.1016/j.intimp.2024.112559
[4] Zhu H, Wang Y, He YB, et al. Inflammation-mediated macrophage polarization induces TRPV1/TRPA1 heteromers in endometriosis[J]. Am J Transl Res, 2022, 14(5): 3066-3078.
[5] Neziri AY, Bersinger NA, Andersen OK, et al. Correlation between altered central pain processing and concentration of peritoneal fluid inflammatory cytokines in endometriosis patients with chronic pelvic pain[J]. Reg Anesth Pain Med, 2014, 39(3): 181-184.
[6] Liang YC, Liu D, Yang F, et al. Perineural invasion in endometriotic lesions contributes to endometriosis-associated pain[J]. J Pain Res, 2018, 11: 1999-2009. doi:10.2147/JPR.S168715
[7] van Barneveld E, Manders J, van Osch FHM, et al. Depression, anxiety, and correlating factors in endometriosis: a systematic review and meta-analysis[J]. J Womens Health, 2022, 31(2): 219-230.
[8] Wu MH, Hsiao KY, Tsai SJ. Hypoxia: the force of endometriosis[J]. J Obstet Gynaecol Res, 2019, 45(3): 532-541.
[9] Zhou Y, Jin Y, Wang Y, et al. Hypoxia activates the unfolded protein response signaling network: an adaptive mechanism for endometriosis[J]. Front Endocrinol, 2022, 13: 945578. doi:10.3389/fendo.2022.945578
[10] Anvari Aliabad R, Hassanpour K, Norooznezhad AH. Cannabidiol as a possible treatment for endometriosis through suppression of inflammation and angiogenesis[J]. Immun Inflamm Dis, 2024, 12(8): e1370. doi:10.1002/iid3.1370
[11] Yu YX, Xiu YL, Chen X, et al. Transforming growth factor-beta 1 involved in the pathogenesis of endometriosis through regulating expression of vascular endothelial growth factor under hypoxia[J]. Chin Med J, 2017, 130(8): 950-956.
[12] Ajdary M, Kashi AM, Derakhshan R, et al. NLRP3 concentration, oxidants, and antioxidants in plasma of endometriosis patients undergoing treatment with die-nogest[J]. J Gynecol Obstet Hum Reprod, 2024, 53(3): 102744. doi:10.1016/j.jogoh.2024.102744
[13] Maeda N, Izumiya C, Taniguchi K, et al. Dienogest improves human leucocyte antigen-DR underexpression and reduces tumour necrosis factor-α production in peritoneal fluid cells from women with endometriosis[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 177: 48-51. doi:10.1016/j.ejogrb.2014.03.019
[14] Kim HJ, Kim SH, Oh YS, et al. Dienogest may reduce estradiol- and inflammatory cytokine-induced cell viability and proliferation and inhibit the pathogenesis of endometriosis: a cell culture- and mouse model-based study[J]. Biomedicines, 2022, 10(11): 2992. doi:10.3390/biomedicines10112992
[15] Yamanaka K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E(2)production in human endometriotic stromal cells in spheroid culture[J]. Fertil Steril, 2012, 97(2): 477-482.
[16] Mita S, Shimizu Y, Notsu T, et al. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells[J]. Fertil Steril, 2011, 96(6): 1485-1489.
[17] Mita S, Nakakuki M, Ichioka M, et al. Dienogest inhi-bits C-C motif chemokine ligand 20 expression in human endometriotic epithelial cells[J]. Eur J Obstet Gynecol Reprod Biol, 2017, 214: 65-70. doi:10.1016/j.ejogrb.2017.04.048
[18] Grandi G, Mueller M, Bersinger N, et al. Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells[J]. Am J Reprod Immunol, 2016, 76(4): 292-298.
[19] Ichioka M, Mita S, Shimizu Y, et al. Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells[J]. J Steroid Biochem Mol Biol, 2015, 147: 103-110. doi:10.1016/j.jsbmb.2014.12.008
[20] de Vries Lentsch S, Rubio-Beltrán E, MaassenVanDenBrink A. Changing levels of sex hormones and calcitonin gene-related peptide(CGRP)during a womans life: Implications for the efficacy and safety of novel antimigraine medications[J]. Maturitas, 2021, 145: 73-77. doi:10.1016/j.maturitas.2020.12.012
[21] Chaichian S, Firoozabadi ZD, Rokhgireh S, et al. CGRP neuropeptide levels in patients with endometriosis-related pain treated with dienogest: a comparative study[J]. BMC Womens Health, 2024, 24(1): 257. doi:10.1186/s12905-024-03095-y
[22] Yano M, Matsuda A, Natsume T, et al. Pain-related behavior and brain activation in Cynomolgus macaques with naturally occurring endometriosis[J]. Hum Reprod, 2019, 34(3): 469-478.
[23] Choi J, Jo M, Lee E, et al. Dienogest regulates apoptosis, proliferation, and invasiveness of endometriotic cyst stromal cells via endoplasmic reticulum stress induction[J]. Mol Hum Reprod, 2020, 26(1): 30-39.
[24] Prechapanich J, Kajihara T, Fujita K, et al. Effect of a dienogest for an experimental three-dimensional endometrial culture model for endometriosis[J]. Med Mol Morphol, 2014, 47(4): 189-195.
[25] Fu L, Osuga Y, Morimoto C, et al. Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometrio-tic stromal cells[J]. Fertil Steril, 2008, 89(5 Suppl): 1344-1347.
[26] Shimizu Y, Takeuchi T, Mita S, et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression[J]. Mol Hum Reprod, 2009, 15(10): 693-701.
[27] McKinnon BD, Bertschi D, Bersinger NA, et al. Inflammation and nerve fiber interaction in endometriotic pain[J]. Trends Endocrinol Metab, 2015, 26(1): 1-10.
[28] Fischer OM, Kaufmann-Reiche U, Moeller C, et al. Effects of dienogest on surgically induced endometriosis in rats after repeated oral administration[J]. Gynecol Obstet Invest, 2011, 72(3): 145-151.
[29] Katayama H, Katayama T, Uematsu K, et al. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model[J]. Hum Reprod, 2010, 25(11): 2851-2858.
[30] Lin SC, Li WN, Lin SC, et al. Targeting YAP1 ameliorates progesterone resistance in endometriosis[J]. Hum Reprod, 2023, 38(6): 1124-1134.
[31] Techatraisak K, Hestiantoro A, Ruey S, et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis(ENVISIOeN): interim results from a prospective cohort study under real-life cli-nical practice[J]. BMC Womens Health, 2019, 19(1): 68. doi:10.1186/s12905-019-0758-6
[32] Caruso S, Iraci M, Cianci S, et al. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain[J]. J Pain Res, 2019, 12: 2371-2378. doi:10.2147/JPR.S207599
[33] Techatraisak K, Hestiantoro A, Soon R, et al. Impact of long-term dienogest therapy on quality of life in Asian women with endometriosis: the prospective non-interventional study ENVISIOeN[J]. Reprod Sci, 2022, 29(4): 1157-1169.
[34] Uludag SZ, Demirtas E, Sahin Y, et al. Dienogest reduces endometrioma volume and endometriosis-related pain symptoms[J]. J Obstet Gynaecol, 2021, 41(8): 1246-1251.
[35] Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain[J]. Gynecol Endocrinol, 2020, 36(1): 81-83.
[36] Vignali M, Belloni GM, Pietropaolo G, et al. Effect of Dienogest therapy on the size of the endometrioma[J]. Gynecol Endocrinol, 2020, 36(8): 723-727.
[37] Ma Y, Wang W X, Zhao Y. Dienogest in conjunction with GnRH-a for postoperative management of endometriosis [J]. Front Pharmacol, 2024, 15: 1373582. doi:10.3389/fphar.2024.1373582
[38] Karata?瘙塂 E, Temiz BE, Mümü?瘙塂oglu S, et al. The effect of dienogest treatment on anti-Mullerian hormone in patients with endometrioma: a 12-month follow-up study[J]. J Turk Ger Gynecol Assoc, 2024, 25(2): 102-106.
[39] Wu H, Liu JJ, Ye ST, et al. Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: a meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2024, 297: 40-49. doi:10.1016/j.ejogrb.2024.03.032.
[40] Paulo Leonardo-Pinto J, Laguna Benetti-Pinto C, Angerame Yela D. When solving dyspareunia is not enough to restore sexual function in women with deep infiltrating endometriosis treated with dienogest[J]. J Sex Marital Ther, 2019, 45(1): 44-49.
[41] Maiorana A, Maranto M, Restivo V, et al. Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis[J]. Arch Gynecol Obstet, 2024, 309(2): 589-597.
[42] Lee SR, Yi KW, Song JY, et al. Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma[J]. Reprod Sci, 2018, 25(3): 341-346.
[43] 孙佳凡, 王湘炼, 余文念, 等. 地诺孕素对卵巢子宫内膜异位囊肿的疗效及安全性研究[J]. 中华妇产科杂志, 2024, 59(9): 692-701. SUN Jiafan, WANG Xianglian, YU Wennian, et al. Efficacy and safety of dienogest on ovarian endometrioma[J]. Chinese Journal of Obstetrics and Gynecology, 2024, 59(9): 692-701.
[44] Cho B, Roh JW, Park J, et al. Safety and effectiveness of dienogest(visanne^®)for treatment of endometriosis: a large prospective cohort study[J]. Reprod Sci, 2020, 27(3): 905-915.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed